Alexander M. M. Eggermont
Research Subjects
Research Interests
Alexander M. M. Eggermont has a total of 175 co-authors. Here are the top co-authors by number of shared publications:
- Caroline Robert
Département de Médecine Oncologique, Gustave Roussy, Villejuif, France
7 shared publications Stefan Suciu
EORTC Headquarters, Brussels, Belgium
7 shared publications- Alessandro Testori
European Institute of Oncology, Milan, Italy
5 shared publications Reinhard Dummer
University of Zurich Hospital, Zurich, Switzerland
5 shared publications- Jean-Jacques Grob
Department of Dermatology, AP-HM Timone Hospital, Marseille, France
4 shared publications - Michele Maio
Center for Immuno-Oncology, University Hospital of Siena, University of Siena, Siena, Italy
4 shared publications
Latest Publications
- 1 June 2020
- Published by Elsevier in Bulletin du Cancer
- Vol. 107 (6) , 640-641
The impact of the immunotherapy revolution on lymph nodal surgery
- 1 June 2020
- Published by Elsevier in Bulletin du Cancer
- Vol. 107 (6) , 640-641
The impact of the immunotherapy revolution on lymph nodal surgery
- 1 September 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 119, 1-10
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
- 1 September 2019
- Published by Elsevier in European Journal of Cancer
- Vol. 119, 1-10
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
- 4 April 2019
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (14) , 1374-1377
Estimation of Distant Metastasis–free Survival in Trials of Adjuvant Therapy for Melanoma
To the Editor: Recently, trials of adjuvant therapy for melanoma in which therapies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), or BRAF and MEK are assessed have reported positive results in terms of relapse-free survival and distant metastasis–free survival.1-4 The European Organization for Research and Treatment of Cancer (EORTC) 18071 trial1 compared ipilimumab with placebo in patients with resected stage III melanoma; the CheckMate 238 trial2 compared nivolumab with ipilimumab in patients with resected stage IIIB, IIIC, or IV melanoma; and the COMBI-AD trial (Nov. 9, 2017, issue)3,4 compared dabrafenib plus trametinib with placebo in patients . . .
- 4 April 2019
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 380 (14) , 1374-1377
Estimation of Distant Metastasis–free Survival in Trials of Adjuvant Therapy for Melanoma
To the Editor: Recently, trials of adjuvant therapy for melanoma in which therapies that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death 1 (PD-1), or BRAF and MEK are assessed have reported positive results in terms of relapse-free survival and distant metastasis–free survival.1-4 The European Organization for Research and Treatment of Cancer (EORTC) 18071 trial1 compared ipilimumab with placebo in patients with resected stage III melanoma; the CheckMate 238 trial2 compared nivolumab with ipilimumab in patients with resected stage IIIB, IIIC, or IV melanoma; and the COMBI-AD trial (Nov. 9, 2017, issue)3,4 compared dabrafenib plus trametinib with placebo in patients . . .
- Open Access
- 18 January 2019
- Published by Wiley in Molecular Oncology
- Vol. 13 (3) , 521-527
Cancer Core Europe: A translational research infrastructure for a European mission on cancer
Cancer Core Europe is a European legal alliance consisting of seven leading cancer centres – most of them Comprehensive Cancer Centres (CCCs) – with a single portal system to engage in various research projects with partners. Cancer Core Europe was established to create a sustainable, high‐level, shared research infrastructure platform hosting research collaborations and task forces (data sharing, clinical trials, genomics, immunotherapy, imaging, education and training, and legal and ethical issues), with a controlled expansion agenda. Translational cancer research covers the cancer research continuum from basic to preclinical to early clinical, late clinical, and outcomes research. Basic–preclinical research serves as the ‘engine’ for early clinical research by bridging the early translational research gap and is the primary and current focus of the consortium as exemplified by the launching of the Basket of Baskets trial, Europe's largest precision cancer medicine trial. Inspired by the creation of Cancer Core Europe, the prevention community established Cancer Prevention Europe, a consortium of ten cancer prevention centres aimed at supporting the complete prevention research continuum. Presently, Cancer Core Europe and Cancer Prevention Europe are integrating therapeutics and prevention strategies to address in partnership the widening cancer problem. By providing innovative approaches for cancer research, links to healthcare systems, development of quality‐assured multidisciplinary cancer care, and assessment of long‐term outcomes, the virtual infrastructure will serve as a hub to connect and interact with other centres across Europe and beyond. Together, Cancer Core Europe and Cancer Prevention Europe are prepared to function as a central engine to tackle, in collaboration with various partners, a potential ‘mission on cancer’ addressing the cancer burden.
- 18 January 2019
- Published by Wiley in Molecular Oncology
- Vol. 13 (3) , 521-527
Open AccessCancer Core Europe: A translational research infrastructure for a European mission on cancer
Cancer Core Europe is a European legal alliance consisting of seven leading cancer centres – most of them Comprehensive Cancer Centres (CCCs) – with a single portal system to engage in various research projects with partners. Cancer Core Europe was established to create a sustainable, high‐level, shared research infrastructure platform hosting research collaborations and task forces (data sharing, clinical trials, genomics, immunotherapy, imaging, education and training, and legal and ethical issues), with a controlled expansion agenda. Translational cancer research covers the cancer research continuum from basic to preclinical to early clinical, late clinical, and outcomes research. Basic–preclinical research serves as the ‘engine’ for early clinical research by bridging the early translational research gap and is the primary and current focus of the consortium as exemplified by the launching of the Basket of Baskets trial, Europe's largest precision cancer medicine trial. Inspired by the creation of Cancer Core Europe, the prevention community established Cancer Prevention Europe, a consortium of ten cancer prevention centres aimed at supporting the complete prevention research continuum. Presently, Cancer Core Europe and Cancer Prevention Europe are integrating therapeutics and prevention strategies to address in partnership the widening cancer problem. By providing innovative approaches for cancer research, links to healthcare systems, development of quality‐assured multidisciplinary cancer care, and assessment of long‐term outcomes, the virtual infrastructure will serve as a hub to connect and interact with other centres across Europe and beyond. Together, Cancer Core Europe and Cancer Prevention Europe are prepared to function as a central engine to tackle, in collaboration with various partners, a potential ‘mission on cancer’ addressing the cancer burden.
- 9 August 2018
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 379 (6) , 593-595
Adjuvant Pembrolizumab in Resected Stage III Melanoma
To the Editor: In the past 2 years, Eggermont et al. have reported the findings of two landmark trials of adjuvant immunotherapy for stage III melanoma: the European Organization for the Research and Treatment of Cancer (EORTC) 18071 trial of ipilimumab1 and the EORTC 1325 trial of pembrolizumab (May 10 issue).2 Both trials suggest that adjuvant immunotherapy had a smaller effect on preventing locoregional recurrence than on preventing distant metastases. Neither article provides details on regional recurrence in patients at high risk for this event, such as those with macroscopic involvement of large or multiple lymph nodes or those with . . .
- 9 August 2018
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 379 (6) , 593-595
Adjuvant Pembrolizumab in Resected Stage III Melanoma
To the Editor: In the past 2 years, Eggermont et al. have reported the findings of two landmark trials of adjuvant immunotherapy for stage III melanoma: the European Organization for the Research and Treatment of Cancer (EORTC) 18071 trial of ipilimumab1 and the EORTC 1325 trial of pembrolizumab (May 10 issue).2 Both trials suggest that adjuvant immunotherapy had a smaller effect on preventing locoregional recurrence than on preventing distant metastases. Neither article provides details on regional recurrence in patients at high risk for this event, such as those with macroscopic involvement of large or multiple lymph nodes or those with . . .
- 30 May 2018
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 15 (9) , 535-536
The new era of adjuvant therapies for melanoma
- 30 May 2018
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 15 (9) , 535-536
The new era of adjuvant therapies for melanoma
- 14 December 2017
- Published by Springer Nature
- p. 579-591
Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting
- 14 December 2017
- Published by Springer Nature
- p. 579-591
Melanoma: Immunotherapy in Advanced Melanoma and in the Adjuvant Setting
- Open Access
- 3 November 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 1-10
The need for a network to establish and validate predictive biomarkers in cancer immunotherapy
Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, the entire medical oncology field has been revolutionized by the introduction of immune checkpoints inhibitors. Despite success in a variety of malignancies, responses typically only occur in a small percentage of patients for any given histology or treatment regimen. There are also concerns that immunotherapies are associated with immune-related toxicity as well as high costs. As such, identifying biomarkers to determine which patients are likely to derive clinical benefit from which immunotherapy and/or be susceptible to adverse side effects is a compelling clinical and social need. In addition, with several new immunotherapy agents in different phases of development, and approved therapeutics being tested in combination with a variety of different standard of care treatments, there is a requirement to stratify patients and select the most appropriate population in which to assess clinical efficacy. The opportunity to design parallel biomarkers studies that are integrated within key randomized clinical trials could be the ideal solution. Sample collection (fresh and/or archival tissue, PBMC, serum, plasma, stool, etc.) at specific points of treatment is important for evaluating possible biomarkers and studying the mechanisms of responsiveness, resistance, toxicity and relapse. This white paper proposes the creation of a network to facilitate the sharing and coordinating of samples from clinical trials to enable more in-depth analyses of correlative biomarkers than is currently possible and to assess the feasibilities, logistics, and collated interests. We propose a high standard of sample collection and storage as well as exchange of samples and knowledge through collaboration, and envisage how this could move forward using banked samples from completed studies together with prospective planning for ongoing and future clinical trials.
- 3 November 2017
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 15 (1) , 1-10
Open AccessThe need for a network to establish and validate predictive biomarkers in cancer immunotherapy
Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, the entire medical oncology field has been revolutionized by the introduction of immune checkpoints inhibitors. Despite success in a variety of malignancies, responses typically only occur in a small percentage of patients for any given histology or treatment regimen. There are also concerns that immunotherapies are associated with immune-related toxicity as well as high costs. As such, identifying biomarkers to determine which patients are likely to derive clinical benefit from which immunotherapy and/or be susceptible to adverse side effects is a compelling clinical and social need. In addition, with several new immunotherapy agents in different phases of development, and approved therapeutics being tested in combination with a variety of different standard of care treatments, there is a requirement to stratify patients and select the most appropriate population in which to assess clinical efficacy. The opportunity to design parallel biomarkers studies that are integrated within key randomized clinical trials could be the ideal solution. Sample collection (fresh and/or archival tissue, PBMC, serum, plasma, stool, etc.) at specific points of treatment is important for evaluating possible biomarkers and studying the mechanisms of responsiveness, resistance, toxicity and relapse. This white paper proposes the creation of a network to facilitate the sharing and coordinating of samples from clinical trials to enable more in-depth analyses of correlative biomarkers than is currently possible and to assess the feasibilities, logistics, and collated interests. We propose a high standard of sample collection and storage as well as exchange of samples and knowledge through collaboration, and envisage how this could move forward using banked samples from completed studies together with prospective planning for ongoing and future clinical trials.